<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28029563</identifier>
<setSpec>1578-8865</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Escobar, C</dc:author>
<dc:author>Barrios, V</dc:author>
<dc:author>Polo, J</dc:author>
<dc:author>Lobos, J M</dc:author>
<dc:author>Vargas, D</dc:author>
<dc:description xml:lang="en">OBJECTIVES Approximately 40% of patients with non-valvular auricular fibrillation (NVAF) who receive vitamin K antagonists (VKA) in Primary Care in Spain have poor anticoagulation control. The objective of the study Actuación en antiCoagulación, Tratamiento y Uso de anticoagulantes orales de acción directa (ACOD) en Atención primaria (ACTUA) (Action in Coagulation, Treatment and Use of direct oral anticoagulants [DOACs]) in Primary Care) was to analyse the current situation regarding the use of VKA and non-vitamin K antagonist oral anticoagulants (NOACs) in patients with NVAF in Primary Care in Spain and the possible issues arising from it. PATIENTS AND METHODS An online survey was created covering various aspects of the use of oral anticoagulants in NAFV. A two-round modified Delphi approach was used. Results were compiled as a set of practical guidelines. RESULTS Forty-four experts responded to the survey. Consensus was reached in 62% (37/60) of the items. Experts concluded that a considerable number of patients with NVAF who receive VKA do not have a well-controlled INR and that a substantial group of patients who could benefit from being treated with NOACs do not receive them. The use of NOACs increases the probability of having good anticoagulation control and decreases the risk of severe and intracranial haemorrhage. Current limitations to the use of NOACs include administrative barriers, insufficient knowledge about the benefits and risks of NOACs, limited experience of doctors in using them, and their price. Renal insufficiency influences the choice of a particular anticoagulant. CONCLUSIONS The ACTUA study highlights the existing controversies about the use of oral anticoagulants for the treatment of NVAF in Primary Care in Spain, and provides consensus recommendations that may help to improve the use of these medications.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Delphi process</dc:subject>
<dc:subject>Método Delphi</dc:subject>
<dc:subject>Nonvalvular atrial fibrillation</dc:subject>
<dc:subject>Vitamin K antagonists</dc:subject>
<dc:subject>Antagonistas de la vitamina K</dc:subject>
<dc:subject>Anticoagulation</dc:subject>
<dc:subject>Direct oral anticoagulants</dc:subject>
<dc:subject>Anticoagulantes orales de acción directa</dc:subject>
<dc:subject>Anticoagulación</dc:subject>
<dc:subject>Fibrilación auricular no valvular</dc:subject>
<dc:date>2017 Oct </dc:date>
<dc:title xml:lang="es">Uso de los anticoagulantes orales de acción directa en atención primaria: Estudio ACTUA.</dc:title>
<dc:title xml:lang="en">[Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study].</dc:title>
<dc:publisher>Semergen</dc:publisher>
</metadata>
</record>
</pubmed-document>
